Sagimet Biosciences Inc.
SGMT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | 100% | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -1,537% | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -1,393.8% | – | – |
| EPS Diluted | -1.45 | -1.53 | -1.38 | -1.1 |
| % Growth | 5.2% | -10.9% | -25.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |